Jones JO - Search Results

1

Vitamin K epoxide reductase expression and prostate cancer risk.

Tew BY, Pal SK, He M, Tong T, Wu H, Hsu J, Liu X, Neuhausen SL, Jones JO. Tew BY, et al. Among authors: jones jo. Urol Oncol. 2017 Mar;35(3):112.e13-112.e18. doi: 10.1016/j.urolonc.2016.10.020. Epub 2016 Nov 23. Urol Oncol. 2017. PMID: 27889279

2

Vitamin K epoxide reductase regulation of androgen receptor activity.

Tew BY, Hong TB, Otto-Duessel M, Elix C, Castro E, He M, Wu X, Pal SK, Kalkum M, Jones JO. Tew BY, et al. Among authors: jones jo. Oncotarget. 2017 Feb 21;8(8):13818-13831. doi: 10.18632/oncotarget.14639. Oncotarget. 2017. PMID: 28099154 Free PMC article.

3

Synaptophysin expression on circulating tumor cells in patients with castration resistant prostate cancer undergoing treatment with abiraterone acetate or enzalutamide.

Pal SK, He M, Chen L, Yang L, Pillai R, Twardowski P, Hsu J, Kortylewski M, Jones JO. Pal SK, et al. Among authors: jones jo. Urol Oncol. 2018 Apr;36(4):162.e1-162.e6. doi: 10.1016/j.urolonc.2017.12.006. Epub 2017 Dec 27. Urol Oncol. 2018. PMID: 29289429 Free PMC article.

4

Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy.

Pal SK, Moreira D, Won H, White SW, Duttagupta P, Lucia M, Jones J, Hsu J, Kortylewski M. Pal SK, et al. Int J Mol Sci. 2019 Apr 13;20(8):1831. doi: 10.3390/ijms20081831. Int J Mol Sci. 2019. PMID: 31013891 Free PMC article.

5

RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic renal cell carcinoma.

Pal SK, He M, Tong T, Wu H, Liu X, Lau C, Wang JH, Warden C, Wu X, Signoretti S, Choueiri TK, Karam JA, Jones JO. Pal SK, et al. Among authors: jones jo. Mol Cancer Res. 2015 Jan;13(1):130-7. doi: 10.1158/1541-7786.MCR-14-0352. Epub 2014 Sep 2. Mol Cancer Res. 2015. PMID: 25183163 Free PMC article.

6

Detection and phenotyping of circulating tumor cells in high-risk localized prostate cancer.

Pal SK, He M, Wilson T, Liu X, Zhang K, Carmichael C, Torres A, Hernandez S, Lau C, Agarwal N, Kawachi M, Yen Y, Jones JO. Pal SK, et al. Among authors: jones jo. Clin Genitourin Cancer. 2015 Apr;13(2):130-6. doi: 10.1016/j.clgc.2014.08.014. Epub 2014 Sep 22. Clin Genitourin Cancer. 2015. PMID: 25450039 Free PMC article.

7

Circulating tumor cells in prostate cancer: Does (nuclear) size matter?

Pal SK, Agarwal N, Jones JO. Pal SK, et al. Among authors: jones jo. Cancer. 2015 Sep 15;121(18):3190-2. doi: 10.1002/cncr.29454. Epub 2015 May 14. Cancer. 2015. PMID: 25980931 Free article. No abstract available.

8

Clinical and Translational Assessment of VEGFR1 as a Mediator of the Premetastatic Niche in High-Risk Localized Prostate Cancer.

Pal SK, Vuong W, Zhang W, Deng J, Liu X, Carmichael C, Ruel N, Pinnamaneni M, Twardowski P, Lau C, Yu H, Figlin RA, Agarwal N, Jones JO. Pal SK, et al. Among authors: jones jo. Mol Cancer Ther. 2015 Dec;14(12):2896-900. doi: 10.1158/1535-7163.MCT-15-0367. Epub 2015 Oct 8. Mol Cancer Ther. 2015. PMID: 26450920 Clinical Trial.

9

The role of peroxisome proliferator-activated receptor gamma in prostate cancer.

Elix C, Pal SK, Jones JO. Elix C, et al. Among authors: jones jo. Asian J Androl. 2018 May-Jun;20(3):238-243. doi: 10.4103/aja.aja_15_17. Asian J Androl. 2018. PMID: 28597850 Free PMC article. Review.

10

The androgen receptor malignancy shift in prostate cancer.

Copeland BT, Pal SK, Bolton EC, Jones JO. Copeland BT, et al. Among authors: jones jo. Prostate. 2018 May;78(7):521-531. doi: 10.1002/pros.23497. Epub 2018 Feb 23. Prostate. 2018. PMID: 29473182 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

116 results

Search Page

Filters